Raf

Pan-RAF kinase inhibitor 1 is a selective inhibitor targeting the Pan-RAF kinase family, modulating the MAPK signaling pathway. This compound effectively suppresses the proliferation of RAS-mutant tumor cells, making it a valuable tool for investigating cancer biology. Its applications include research focused on therapeutic strategies for cancer treatment, particularly in the context of RAS mutations.

Anticancer Agent 124 is a potent and selective pan RAF inhibitor that acts primarily on the RAF family of kinases. It effectively suppresses MAPK signaling in tumor cells harboring BRAF V600E, NRAS, and KRAS mutations. This compound is suitable for research applications aimed at understanding the role of RAF-mediated pathways in cancer progression and therapeutic resistance.

C-RAF kinase-IN-1 is a selective inhibitor of C-RAF kinase, demonstrating an IC50 value of 0.193 μM. As a quinoline derivative, it plays a significant role in inhibiting C-RAF-mediated signaling pathways. This compound is primarily utilized in cancer research, providing insights into therapeutic targeting and the underlying mechanisms of cancer progression.

B-Raf IN 5 is a highly effective B-Raf inhibitor, demonstrating an IC50 of 2.0 nM. This compound selectively targets B-Raf without binding to the secondary target PXR and exhibits resistance to rapid metabolism. B-Raf IN 5 is ideal for research applications focused on cancer biology and therapeutic interventions targeting B-Raf-driven malignancies.

SB-699393 is a potent BRAF inhibitor with a dissociation constant (Kd) of 7.2 nM, demonstrating the ability to effectively cross the blood-brain barrier. This makes SB-699393 a valuable tool for investigating the role of BRAF in neurological conditions, including stroke. Its selective inhibition of BRAF can aid in the elucidation of signaling pathways and therapeutic strategies in related research applications.

B-Raf IN 13 is a potent BRAF inhibitor, demonstrating an IC50 of 3.55 nM in assays targeting the BRAF V600E mutant enzyme. This compound exhibits significant anti-cancer activity, making it a valuable tool for research into targeted therapies for cancers associated with BRAF mutations. Its application spans studies focused on the modulation of cellular signaling pathways linked to oncogenesis.

Avutometinib potassium is a potent RAF/MEK inhibitor that effectively prevents MEK phosphorylation by ARAF, BRAF, and CRAF through the formation of dominant negative RAF-MEK complexes. This compound exhibits significant anti-proliferative activity across various tumor cell lines, particularly those with KRAS mutations, including pancreatic ductal adenocarcinoma (PDAC) cell lines. In vivo studies demonstrate that Avutometinib potassium inhibits tumor growth and enhances survival in mouse models of KRAS and p53 mutant pancreatic cancer. It holds potential for research in low-grade serous ovarian carcinoma and other oncogenic conditions involving the RAF/MEK pathway.

LSN3074753 is a pan-RAF inhibitor targeting RAF monomers and dimers, particularly effective against tumor cells with activated MAPK pathways driven by BRAF or KRAS mutations. This reagent exhibits significant antitumor activity, making it a valuable tool for research applications involving colorectal cancer models. In combination with Cetuximab, LSN3074753 produces additive and synergistic effects, highlighting its potential for therapeutic strategies in tumors with specific genetic alterations such as KRAS or BRAF mutations.

SB-682330A is a selective inhibitor of Raf kinase, a key component of the MAPK signaling pathway. This compound demonstrates potent inhibition of Raf, leading to decreased cellular proliferation and survival in cancer cells. SB-682330A is primarily used in research investigating the role of Raf in oncogenic signaling and as a potential therapeutic agent in targeted cancer therapies.

BRAFV600E-IN-2 is a potent BRAFV600E inhibitor with an IC50 of less than 10 nM, demonstrating significant anti-tumor activity. This compound is valuable for research applications focused on targeted cancer therapies, particularly those involving BRAF-mutant tumors. Its efficacy underscores its potential utility in investigating mechanisms of resistance and sensitivity in cancer treatment.

CST905 is a highly effective PROTAC degrader specifically targeting the BRAF-V600E mutation, demonstrating a DC50 value of 18 nM. This compound facilitates the selective degradation of the BRAF-V600E protein, making it a valuable tool for cancer research aimed at understanding and addressing mutant BRAF-driven tumors. Its ability to modulate protein levels through targeted ubiquitination offers significant potential for therapeutic applications in oncology.

B-Raf IN 7 is a potent inhibitor of the B-Raf kinase, demonstrating an IC50 value of 110.23 nM. This compound has shown significant antitumor activity in various cancer cell lines, including colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela), and human prostate cancer (PC-3), with IC50 values ranging from 7.50 to 12.83 µM. B-Raf IN 7 is a valuable tool for research in cancer biology and therapeutic development targeting the RAS/RAF/MEK/ERK signaling pathway.

Pan-Raf/RTK inhibitor 1 (compound I-16) is a highly selective pan-Raf inhibitor that targets the Raf kinases with IC50 values of 3.49 nM for BRafV600E, 8.86 nM for ARaf, 5.78 nM for BRafWT, and 1.65 nM for CRaf. This compound exhibits significant antiproliferative effects across a range of cancer cell lines, making it a valuable tool for cancer research. Its ability to inhibit multiple Raf isoforms facilitates studies investigating the role of the Raf signaling pathway in tumorigenesis and therapeutic resistance.

ISIS 5132 is a phosphorothioate oligonucleotide consisting of 20 bases that specifically targets and down-regulates c-raf expression. By inhibiting the expression of c-raf, this compound modulates downstream signaling pathways involved in cell proliferation and survival. ISIS 5132 is valuable for research applications focused on cancer biology and therapeutic development associated with Raf signaling pathways.

ARQ-736 is a potent and selective inhibitor of the B-RAF kinase, which is integral to the MAPK signaling pathway. This compound demonstrates significant anticancer activity by selectively targeting B-RAF mutations commonly associated with various malignancies. ARQ-736 is valuable for research applications focused on understanding B-RAF-driven cancers and exploring targeted therapeutic strategies.

MEK1/C-Raf-IN-1 is a selective inhibitor of MEK1 and C-Raf, exhibiting IC50 values of 97 nM and 23 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology and therapeutic development. Its effects on MAPK signaling pathways provide insights into potential treatment mechanisms for various malignancies.

RAF-IN-2 is a selective RAF inhibitor that disrupts RAF-MEK-ERK signaling pathways. This compound demonstrates significant activity against various proliferative diseases, including leukemia, psoriasis, and fibrosis. Its application in research facilitates investigations into the mechanisms of these diseases and the potential therapeutic benefits of targeted RAF inhibition.

EBI-907 is a potent and orally active inhibitor of the B-RafV600E mutation. It exhibits significant antiproliferative activity in cancer cell lines, demonstrating IC50 values of 13 nM in A375 and 14 nM in Colo-205 cells. In vivo studies show that EBI-907 effectively induces tumor regression in a Colo-205 xenograft model dependent on B-RafV600E. This compound is a valuable tool for research focused on melanoma and cancers associated with B-RafV600E mutations.

BRAF V600E/CRAF-IN-2 is a potent inhibitor targeting BRAF V600E and CRAF, demonstrating IC50 values of 0.888 μM and 0.229 μM, respectively. This compound induces apoptosis and effectively causes cell cycle arrest at the G0/G1 phase in HCT-116 colon cancer cells. BRAF V600E/CRAF-IN-2 is suitable for research applications focused on cancer biology and treatment strategies.

B-Raf IN 6 is a highly potent inhibitor of the B-Raf protein kinase, exhibiting an IC50 of 1.7 nM. This compound selectively targets B-Raf without significant binding to the secondary target PXR and demonstrates resistance to rapid metabolism. B-Raf IN 6 is valuable for research applications focusing on cancer biology and therapeutic development.

BRAF V600E/CRAF-IN-1 (Compound 8b) is a potent inhibitor targeting BRAF V600E and CRAF. It induces apoptosis and effectively causes cell cycle arrest at the G0/G1 phase in HCT-116 colon cancer cells. This compound is valuable for research into cancer pathophysiology and therapeutic interventions.

RAF-IN-1 is a potent inhibitor of b/cRAF, demonstrating IC50 values of 3.8 nM for cRAF, 36 nM for bRAF wild-type, and 29.4 nM for the bRAFV600E mutant. This compound effectively inhibits cell growth in cancer cell lines harboring the bRAFV600E mutation, with GI50 values of 3.4 nM in H358 and 2.9 nM in A375 cells. RAF-IN-1 is valuable for research in cancer biology, particularly in studies targeting the RAS-RAF-MEK-ERK signaling pathway.

B-Raf IN 14 is a selective inhibitor of the BRAF kinase, exhibiting an IC50 value of 11.08 μM. This compound is valuable in cancer research, particularly in studies investigating BRAF mutations and their role in tumor progression. Its application may extend to evaluating the efficacy of targeted therapies in BRAF-driven malignancies.

PROTAC BRAF-V600E Degrader-2 is a highly selective degrader targeting the BRAF-V600E mutant, with dissociation constants (Kd) of 14.4 nM and 9.5 nM for BRAF and BRAF-V600E, respectively. This compound effectively induces degradation of the BRAF-V600E kinase domain without impacting wild-type BRAF. Its potent biological activity makes it a valuable tool for research applications focused on melanoma cell growth inhibition and the study of BRAF-related signaling pathways.

B-Raf IN 8 is a potent inhibitor of the B-Raf kinase, exhibiting an IC50 of 70.65 nM. This compound demonstrates significant antitumor activity across various cancer cell lines, including hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland cancer (MCF-7), and human prostate cancer (PC-3), with IC50 values of 9.78 µM, 13.78 µM, 18.52 µM, and 29.85 µM, respectively. B-Raf IN 8 is a valuable tool for research into targeted cancer therapies and the mechanistic pathways associated with B-Raf signaling.

Everafenib is a highly selective BRAF inhibitor that effectively penetrates the blood-brain barrier (BBB) and inhibits MAPK signaling pathways. It demonstrates potent activity against various V600E BRAF melanoma cell lines, with IC50 values ranging from 2 to 10 nM, showcasing superior potency compared to other BRAF inhibitors. In vitro and in vivo studies indicate its efficacy in treating metastatic melanoma, including significant effects observed in an intracranial mouse model. This makes Everafenib a valuable tool for cancer research and therapeutic developments targeting BRAF mutations.

B-Raf IN 19 is a specific BRAF inhibitor targeting both BRAF wild-type (BRAF WT) and BRAF V600E mutants, with IC50 values of 0.57 μM and 0.28 μM, respectively. This compound effectively disrupts MAPK signaling pathways in melanoma cells, making it a valuable tool for research focused on cancer signaling mechanisms and therapeutic interventions in melanoma. Its selective inhibition profile supports its use in studies aimed at understanding BRAF-related oncogenic processes.

Raf Inhibitor 3 specifically targets Raf kinases, including B-Raf and C-Raf, with IC50 values below 15 nM. This compound demonstrates potent inhibitory activity, making it a valuable tool for research focused on oncogenic signaling pathways in cancer. Raf Inhibitor 3 is suitable for studying the role of Raf kinases in tumor biology and evaluating potential therapeutic strategies against Raf-dependent malignancies.

B-Raf IN 16 is a selective BRAF inhibitor designed to target the BRAF protein, a key regulator in the MAPK signaling pathway. This cyclic iminopyrimidine derivative exhibits potent anti-cancer activity by impeding the proliferation of BRAF-mutant tumor cells. B-Raf IN 16 is primarily applied in cancer research, aiding in the exploration of targeted therapies for BRAF-related malignancies.

B-Raf IN 18 is a potent B-Raf inhibitor with an IC50 of 3.8 nM. It effectively targets the B-Raf protein, playing a critical role in the MAPK/ERK signaling pathway, which is often dysregulated in various cancers. This compound is suitable for anti-cancer research applications, providing a valuable tool for investigating B-Raf’s involvement in tumor progression and potential therapeutic strategies.

XL-281 is a potent and selective inhibitor of RAF kinase, demonstrating IC50 values of 2.6 nM for CRAF, 4.5 nM for B-RAF, and 6 nM for B-RAFV600E. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. It is particularly relevant for studies targeting RAF signaling pathways in various malignancies.

RAF-IN-4 is a potent Raf Kinase inhibitor, demonstrating IC50 values of 134.3 nM for B-Raf, 118.6 nM for B-Raf (V600E), and 276.7 nM for C-Raf. This compound effectively inhibits the proliferation of cancer cells by targeting the Raf signaling pathway, making it a valuable tool for research in cancer biology, particularly in lung and breast cancer studies. Its selective inhibition of Raf Kinases allows for detailed exploration of their role in oncogenesis and potential therapeutic interventions.

IHMT-RAF-128 is a highly potent pan-RAF inhibitor targeting the RAF kinase family, which plays a crucial role in cell signaling and oncogenesis. This compound exhibits significant antitumor efficacy in xenograft mouse models, demonstrating its potential as a therapeutic agent in cancer research. Notably, IHMT-RAF-128 shows minimal toxicity, making it an attractive candidate for further investigation in oncological studies.

BRAF ligand-1 acts as a specific ligand for the BRAF protein, playing a crucial role in the regulation of cell signaling pathways associated with cell proliferation, survival, and differentiation. This compound is important for studying the BRAF signaling pathway and its implications in various cancers. Additionally, BRAF ligand-1 can be utilized in the synthesis of CST905, further enhancing its utility in biochemical research and drug discovery efforts targeting mutant BRAF.

2-Bromoaldisine is a pyrrole alkaloid that acts as a potent inhibitor of the Raf/MEK/MAPK signaling pathway. It is known to effectively suppress HIV-1 vector infection. This compound is valuable for research applications focused on cancer biology and viral pathogenesis, allowing investigators to study the effects of Raf/MEK/MAPK pathway modulation on cell proliferation and viral replication.